InnoCan Pharma (INNO) Q2 2026 earnings summary

Executive summary

• Reported revenue of US $5.25 million for Q2 2026, a 25.06% decrease year-over-year.

• Gross margin remained strong at 90.8% despite lower sales.

• Operating loss increased to US $0.508 million, up 228.3% year-over-year.

• Flagship skincare brand VALITIC™ maintained Amazon Best Seller and Amazon's Choice status, reflecting strong consumer demand.

• BI Sky subsidiary is expanding sales channels beyond Amazon, including direct-to-consumer and major retail networks.

Financial highlights

• Q2 2026 revenue: US $5.25 million, down 25.06% from Q2 2025.

• Gross profit: US $4.769 million, down 23.0% year-over-year.

• Gross margin: 90.8% in Q2 2026, up from 88.4% in Q2 2025.

• Operating loss: US $0.508 million, compared to a smaller loss in Q2 2025.

• Cash and cash equivalents: US $6.4 million as of June 30, 2026.

Outlook and guidance

• Initiatives underway to diversify sales channels and expand market reach.

• Focus on leveraging established brands and customer base for future growth.

• Expectation of revenue growth and increased brand visibility over the coming year.